RIZE
59 evidence topics · 7 sources
Objective
Location and study date
Study dates in the trial registry
| Milestone | Quoted date |
|---|---|
| Study start (actual) | “2020-02-24” |
| Primary completion (actual) | “2022-04-05” |
| Study completion (actual) | “2022-08-19” |
Number of centers and countries
Study sites listed in the trial registry
Study design
Open-label, repeat-dose study in four sequential ascending-dose cohorts
Design description in the trial registry
Add-on to standard of care with unchanged diet and activity
Eligibility criteria
Congenital hyperinsulinism with persistent hypoglycemia despite standard of care
Exclusion criteria in the primary publication
Inclusion and exclusion criteria in the trial registry, including exclusion of malignancy
Treatment
Dose regimens by cohort in the trial registry
Intravenous infusion over at least 30 minutes every other week, added to standard of care
Inpatient administration and follow-up visits
Study outcomes
Rationale for using percent time in glucose target range 70-180 mg/dL by continuous glucose monitoring as the primary endpoint
Registered primary outcome measures
Primary and key secondary glycemic endpoints in the primary publication
Authors' assessment of time in range as an endpoint in congenital hyperinsulinism
Hypoglycemia events and time in hypoglycemia as the clinically relevant outcomes
Registered secondary outcome measures, including a fasting challenge
Glucose measurement devices and safety assessments
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size not powered for the glycemic endpoints
Participants analyzed in each population
Exclusions from the per-protocol glucometer analyses in the trial registry
Description of analysis sets
Safety, pharmacokinetic, and per-protocol populations
Statistical methods: Wilcoxon signed-rank test of change from baseline
Results
Participant disposition
Screened, enrolled, and completed participants
Protocol violations leading to per-protocol exclusion
Baseline characteristics
Demographics and baseline disease characteristics, intention-to-treat population
| Parameter | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 23) |
|---|---|---|---|---|---|
| Age in years, mean (range) | “5.8 (2–12)” | “9.3 (2–22)” | “5.8 (2–17)” | “4.0 (2–6)” | “6.7 (2–22)” |
| Male, n | “4” | “5” | “3” | “1” | “13 (57%)” |
| KATP channel mutation, n | “1” | “5” | “4” | “1” | “11 (48%)” |
| Unknown genetic etiology | “3” | “2” | “3” | “1” | “9 (39%)” |
| Congenital HI therapy, n (%) | “4” | “7” | “6” | “3” | “20 (87%)” |
| Diazoxide | “2” | “3” | “1” | “2” | “8 (35%)” |
| Somatostatin analog (long acting/short acting) | “2/0” | “2/2” | “3/3” | “1/0” | “8/5 (52%)” |
| Enteral or tube use | “0” | “2” | “3” | “0” | “5 (22%)” |
| Pancreatectomy | “0” | “0” | “3” | “1” | “4 (17%)” |
| History of seizure, n | “4” | “4” | “5” | “3” | “16 (70%)” |
| Hospitalization within the past year, n | “3” | “3” | “6” | “2” | “14 (61%)” |
| Percent time in range (70–180 mg/dL) by CGM, mean (range) | “82 (74–89)” | “74 (66–89)” | “71 (12–90)” | “68 (57–87)” | “74 (12–90)” |
| Percent time in hypoglycemia (<70 mg/dL) by CGM, mean (range) | “16 (11–22)” | “22 (11–32)” | “24 (6–88)” | “29 (11–42)” | “23 (6–88)” |
| Hypoglycemia events/week (<70 mg/dL) by SMBG, mean (range) | “8 (1–13)” | “16 (4–52)” | “15 (7–29)” | “8 (4–11)” | “13 (1–52)” |
Age distribution, background therapy, and history of hospitalization and seizures
Company-reported baseline characteristics
Efficacy results
Primary endpoint: percent time in range 70-180 mg/dL by CGM, per-protocol population
| Measure | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 22) |
|---|---|---|---|---|---|
| Median daily percent time in range at baseline | “81.7” | “72.9” | “83.4” | “59.3” | “76.9” |
| Median daily percent time in range at week 8 | “84.8” | “78.5” | “82.9” | “70.8” | “79.1” |
| Median percent change from baseline | “6.19” | “0.31” | “5.52” | “9.07” | “4.59” |
Primary endpoint: time in range not significantly changed
Key secondary endpoints: hypoglycemia events by SMBG and time in hypoglycemia by CGM, per-protocol population
| Metric | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled, median (range) |
|---|---|---|---|---|---|
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, baseline | “10.1” | “12.5” | “13.0” | “9.3” | “11.5 (4.0–52.0)” |
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, end of treatment | “9.9” | “6.6” | “1.9” | “7.6” | “5.0 (0–23.8)” |
| Hypoglycemia events (<70 mg/dL), % change from baseline (p value) | “−1.6 (NS)” | “−48 (0.016)” | “−84 (0.016)” | “−19.9 (NS)” | “−59 (<0.001)” |
| Severe hypoglycemia events (<50 mg/dL), % change from baseline (p value) | “−40 (NS)” | “−78 (NS)” | “−100 (0.016)” | “−27 (NS)” | “−78 (0.005)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, baseline | “16.3” | “20.3” | “13.7” | “34.4” | “16.2 (6–88)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, end of treatment | “12.3” | “6.7” | “5.4” | “20.4” | “8.5 (0.3–34)” |
| Time in hypoglycemia (<70 mg/dL), % change from baseline (p value) | “−31 (NS)” | “−65 (0.023)” | “−61 (0.016)” | “−47 (NS)” | “−54 (<0.001)” |
| Time in severe hypoglycemia (<50 mg/dL), % change from baseline (p value) | “−22 (NS)” | “−74 (NS)” | “−85 (NS)” | “−61 (NS)” | “−65 (NS)” |
Key secondary endpoints: summary of reductions in hypoglycemia
Overnight hypoglycemia and time above range, per-protocol population
| Endpoint | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg | Pooled |
|---|---|---|---|---|---|
| Overnight (8 h) percent time <70 mg/dL by CGM, % change (p value) | “−15.8 (NS)” | “−54.8 (NS)” | “−55.0 (NS)” | “−61.9 (NS)” | “−52.2 (0.006)” |
| Overnight (8 h) event rate <70 mg/dL by CGM, % change (p value) | “−15.5 (NS)” | “−49.3 (NS)” | “−42.9 (NS)” | “−56.5 (NS)” | “−40.7 (0.04)” |
| Percent time above range (>180 mg/dL) by CGM, net change | “+0.53” | “+6.7” | “+9.4” | “+10.4” | “+6.03” |
| Average overnight glucose (mg/dL) by CGM, net change | “−2.5” | “+21.5” | “+19.3” | “+19.8” | “+17.8” |
Overnight hypoglycemia: congress analysis
Pharmacokinetics and pharmacodynamics
Company-reported results for the pooled 6 and 9 mg/kg doses
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Overall safety: no deaths, adverse drug reactions, or discontinuations
Overview of treatment-emergent adverse events, safety population
| Category | Pre-treatment non-TEAE, total (n = 23) | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, titrate (n = 3) | Ersodetug, total (n = 23) |
|---|---|---|---|---|---|---|
| Participants with adverse events, n (%) | “10 (43)” | “2 (50)” | “7 (88)” | “5 (63)” | “2 (67)” | “16 (70)” |
| Participants with serious adverse events, n (%) | “0 (0)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with investigator-judged study drug-related adverse events, n (%) | “2 (9)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with grade 3 (severe) adverse events, n (%) | “1 (4)” | “0 (0)” | “2 (25)” | “0 (0)” | “0 (0)” | “2 (9)” |
| Participants with grade 4 (life threatening) adverse events, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (13)” | “0 (0)” | “1 (4)” |
Serious adverse events
| Serious adverse event | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg |
|---|---|---|---|---|
| “Hypoglycemia with LOC” | “0” | “1” | “0” | “0” |
| “Tonic-Clonic Seizure” | “0” | “0” | “1” | “0” |
| “Eosinophilic Leukocytosis” | “0” | “1” | “0” | “0” |
Adverse events judged related to study drug, including infusion site reactions
Company-reported exposure margin to nonclinical toxicology studies
Study limitations
Summary
- Design: RIZE was an open-label, uncontrolled study of 23 participants with sequential dose cohorts and 8 weeks of treatment, and its sample size was not powered for the primary or key secondary endpoints.
- Population: participants had congenital hyperinsulinism and were 2 years of age or older, so the study provides indirect evidence of efficacy for adults with tumor hyperinsulinism.
- Outcome: the improvements in hypoglycemia did not translate into a similar improvement in time in range, the registry primary endpoint. The registry reports this endpoint as medians in the per protocol population, while the publication reports means in the intention-to-treat population.
- Reporting: the registry results and the publication differ on sex distribution, and the 2022 company releases describe dosing as “bi-monthly” where the publication gives “every other week (bi-weekly)”.